Literature DB >> 1127718

Nonspecific Immunotherapy of Murine Solid Tumors With Corynebacterium granulosum.

L Milas, B Hunter, K Mason, D Grdina, H Withers.   

Abstract

A single intraperitoneal (ip) or intravenous (iv) injection of Corynebacterium granulosum into C3Hf/Bu mice shortly after subcutaneous (sc) injection of cells from a strongly antigenic syngeneic fibrosarcoma induced by 3-methylcholanthrene caused complete and lasting regressions of 100 and 70% of resulting tumors, respectively. Treatment with this bacterium sc only slightly inhibited the growth of some tumors. C. granulosum given iv to mice 3 days after the sc injection of fibrosarcoma cells caused complete regressions of 39 of 45 tumors; two iv injections with this immunostimulant given 1 month apart were no more effective than a single injection. Intralesional treatment of fibrosarcomas 8 mm in diameter induced complete regressions of tumors in 30% of the animals, whereas sc treatment contralateral to the growing tumor only slightly reduced tumor growth. Intraperitoneal growth of a fibrosarcoma was efficiently controlled (58-80% survival of mice) if C. granulosum was given ip, but not iv, 3 days after inoculation with tumor cells. Again, two injections of C. granulosum (given ip 4 days apart) were only as effective as a single injection. Treatment with C. granulosum iv at 3, 7, 14, or 21 days after sc inoculation of a weakly antigenic, spontaneously arising mammary carcinoma (MC-1) strongly inhibited tumor growth. Three complete but temporary tumor regressions were observed. The subcutaneous growth of another spontaneous mammary carcinoma (MC-2), which contained fairly strong tumor-specific antigen(s), was also significantly inhibited if C. granulosum was given 3,7, or 14 days after, but not 7 days before, tumor cell inoculation. However, pretreatment of mice with the immunostimulant significantly protected the mice against artifically induced pulmonary metastases of this tumor.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1127718

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  8 in total

1.  Glutamate dehydrogenase activity in subcellular fractions of mouse fibrosarcoma.

Authors:  M Hillar; B Lennox
Journal:  Mol Biol Rep       Date:  1979-12-31       Impact factor: 2.316

2.  Spontaneous metastasis: random or selective?

Authors:  L Milas; L J Peters; H Ito
Journal:  Clin Exp Metastasis       Date:  1983 Oct-Dec       Impact factor: 5.150

3.  Antitumor and antimetastatic activity of the differentiating agent N-methylformamide in murine tumor systems.

Authors:  M Iwakawa; P J Tofilon; N Hunter; L C Stephens; L Milas
Journal:  Clin Exp Metastasis       Date:  1987 Oct-Dec       Impact factor: 5.150

4.  Studies on the antitumor activities of pyrimidinone-interferon inducers. Part 2. Potentiation of antitumor resistance mechanisms.

Authors:  L Milas; N Hunter; H Ito; E Lotzová; D A Stringfellow
Journal:  Clin Exp Metastasis       Date:  1983 Jul-Sep       Impact factor: 5.150

5.  A 2.5-year follow-up of local immunotherapy of advanced stomach and intestinal adenocarcinoma with Propionibacterium granulosum.

Authors:  J Gil; A Badowski; T Orlowski; S Szmigielski; H L Ko; J Jeljaszewicz; G Pulverer
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

6.  Treatment with cortisone plus heparin or hexuronyl hexoaminoglycan sulfates of murine tumors and their lung deposits.

Authors:  L Milas; N Hunter; I Basic
Journal:  Clin Exp Metastasis       Date:  1985 Oct-Dec       Impact factor: 5.150

7.  Anti-proliferative effects of Bifidobacterium adolescentis SPM0212 extract on human colon cancer cell lines.

Authors:  Do Kyung Lee; Seok Jang; Mi Jin Kim; Jung Hyun Kim; Myung Jun Chung; Kyung Jae Kim; Nam Joo Ha
Journal:  BMC Cancer       Date:  2008-10-27       Impact factor: 4.430

8.  The effects of N-methylformamide on artificial and spontaneous metastases from a murine hepatocarcinoma.

Authors:  P J Tofilon; C M Vines; L Milas
Journal:  Br J Cancer       Date:  1987-03       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.